Advanced search×

Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model.

Christof C Renner, Nadine N Zemitzsch, Beate B Fuchs, Kathrin D KD Geiger, Matthias M Hermes, Jan J Hengstler, Rolf R Gebhardt, Jürgen J Meixensberger, and Frank F Gaunitz

Mol Cancer (2010) PMID 20053283

It was previously demonstrated that the dipeptide carnosine inhibits growth of cultured cells isolated from patients with malignant glioma. In the present work we investigated whether carnosine also affects tumor growth in vivo and may therefore be considered for human cancer therapy.

DOI: 10.1186/1476-4598-9-2
Version: za2963e q8zab q8zb4 q8zc0 q8zdb q8zed q8zff q8zg3
View PDF

Similar articles you may find interesting…

  1. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF.
    Alois H AH Lang, Heinz H Drexel, ... Axel A Muendlein

    J Mol Diagn 13(1):23-8 (2011) PMID 21227391 PMCID PMC3070579

    View PDF
  2. Protection effects of interferon-gamma in intraocular herpes simplex type 1 infection do not depend on major histo-compatibility complex cla...
    Kathrin D Geiger, Myung-Shik Lee, ... Nora E Sarvetnick

    J Neurovirol 1(5):405 - 409 (1995)

    Buy PDF
  3. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles.
    Sebastian C J SC Steiniger, Jörg J Kreuter, ... Svetlana E SE Gelperina

    Int J Cancer 109(5):759-67 (2004) PMID 14999786

    We have recently shown that doxorubicin bound to polysorbate-coated nanoparticles crossed the intact blood-brain barrier, thus reaching therapeutic concentrations in the brain. Here, we investigated the therapeutic potential of this formulation of doxorubicin in vivo using an animal model created by...
    Buy PDF